Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.7.11.21 - polo kinase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network.
FOXM1 and polo-like kinase 1 are co-ordinately overexpressed in patients with gastric adenocarcinomas.
RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells.
Adenocarcinoma of Lung
[Effect of antisense RNA targeting Polo-like kinase 1 on cell cycle of lung cancer cell line A549]
Adrenal Cortex Neoplasms
Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma.
Adrenocortical Carcinoma
Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma.
Alzheimer Disease
Inhibition of Polo-like kinase 1 reduces beta-amyloid-induced neuronal cell death in Alzheimer's disease.
Inhibition of Polo-like kinase 2 ameliorates pathogenesis in Alzheimer's disease model mice.
Neuronal polo-like kinase in Alzheimer disease indicates cell cycle changes.
Anemia, Aplastic
Deregulation of vital mitotic kinase-phosphatase signaling in hematopoietic stem/progenitor compartment leads to cellular catastrophe in experimental aplastic anemia.
Aneurysm
Plk1 regulates contraction of postmitotic smooth muscle cells and is required for vascular homeostasis.
Aortic Rupture
Plk1 regulates contraction of postmitotic smooth muscle cells and is required for vascular homeostasis.
Arthritis, Rheumatoid
siRNA targeting PLK-1 induces apoptosis of synoviocytes in rheumatoid arthritis.
Ataxia Telangiectasia
Polo-like kinase 1 inactivation following mitotic DNA damaging treatments is independent of ataxia telangiectasia mutated kinase.
Atrial Fibrillation
Diminished PLK2 Induces Cardiac Fibrosis and Promotes Atrial Fibrillation.
Brain Neoplasms
Polo-Like Kinase 1 (PLK1) Inhibition Kills Glioblastoma Multiforme Brain Tumour Cells in Part Through Loss of SOX2 and Delays Tumour Progression in Mice.
Polo-Like Kinase 4 (PLK4) Is Overexpressed in Central Nervous System Neuroblastoma (CNS-NB).
ROS-Responsive Polymeric siRNA Nanomedicine Stabilized by Triple Interactions for the Robust Glioblastoma Combinational RNAi Therapy.
Breast Neoplasms
Anticancer effects of radiation therapy combined with Polo-Like Kinase 4 (PLK4) inhibitor CFI-400945 in triple negative breast cancer.
Augmented expression of Polo-like kinase 1 is a strong predictor of shorter cancer-specific overall survival in early stage breast cancer at 15-year follow-up.
Bioinformatics analysis of key genes in triple negative breast cancer and validation of oncogene PLK1.
Calcium-dependent inhibition of polo-like kinase 3 activity by CIB1 in breast cancer cells.
Characterization of adipose-derived stem cells from subcutaneous and visceral adipose tissues and their function in breast cancer cells.
Circular RNA circPLK1 promotes breast cancer cell proliferation, migration and invasion by regulating miR-4500/IGF1 axis.
Dendrimer mediated targeting of siRNA against polo-like kinase for the treatment of triple negative breast cancer.
Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
Detection of the Cell Cycle-Regulated Negative Feedback Phosphorylation of Mitogen-Activated Protein Kinases in Breast Carcinoma using Nanofluidic Proteomics.
Differentially expressed transcripts and dysregulated signaling pathways and networks in African American breast cancer.
DNA methylation data for identification of epigenetic targets of resveratrol in triple negative breast cancer cells.
Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer.
Expression of Polo-Like Kinase 4(PLK4) in Breast Cancer and Its Response to Taxane-Based Neoadjuvant Chemotherapy.
Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.
High expression of polo-like kinase 1 is associated with TP53 inactivation, DNA repair deficiency, and worse prognosis in ER positive Her2 negative breast cancer.
Identification of key genes in glioblastoma-associated stromal cells using bioinformatics analysis.
Identifying breast cancer subtypes associated modules and biomarkers by integrated bioinformatics analysis.
Immunohistochemical detection of Polo-like Kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcome.
Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain.
LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice.
Matrix metalloproteinase 2-responsive micelle for siRNA delivery.
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI).
Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor.
PLK1 Inhibition Down-regulates Polycomb Group Protein BMI1 via Modulation of the miR-200c/141 Cluster.
PLK1 Inhibition Sensitizes Breast Cancer Cells to Radiation via Suppressing Autophagy.
Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer.
Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.
Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications.
Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer.
Potentiation of cell killing by fractionated radiation and suppression of proliferative recovery in MCF-7 breast tumor cells by the Vitamin D3 analog EB 1089.
Resveratrol inhibits cell cycle progression by targeting Aurora kinase A and Polo-like kinase 1 in breast cancer cells.
Selective transferrin coating as a facile strategy to fabricate BBB-permeable and targeted vesicles for potent RNAi therapy of brain metastatic breast cancer in vivo.
SKA3 Promotes Cell Growth in Breast Cancer by Inhibiting PLK-1 Protein Degradation.
Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumour-initiating cells.
Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis.
Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors.
Burkitt Lymphoma
A specific inhibitor of polo-like kinase 1, GSK461364A, suppresses proliferation of Raji Burkitt's lymphoma cells through mediating cell cycle arrest, DNA damage, and apoptosis.
BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells.
Carcinogenesis
A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer.
Circular RNA circPLK1 promotes breast cancer cell proliferation, migration and invasion by regulating miR-4500/IGF1 axis.
Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage.
Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis.
Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors.
Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma.
Intrahepatic hepatitis B virus large surface antigen induces hepatocyte hyperploidy via failure of cytokinesis.
Knocking down of Polo-like kinase 2 inhibits cell proliferation and induced cell apoptosis in human glioma cells.
LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice.
Low dietary folate initiates intestinal tumors in mice, with altered expression of G2-M checkpoint regulators polo-like kinase 1 and cell division cycle 25c.
Mutual regulation between Polo-like kinase 3 and SIAH2 E3 ubiquitin ligase defines a regulatory network that fine-tunes the cellular response to hypoxia and nickel.
PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis.
PLK-1: Angel or devil for cell cycle progression.
Plk1-mediated phosphorylation of Topors regulates p53 stability.
Polo-like kinase 1 depletion induces DNA damage in early S prior to caspase activation.
Polo-Like Kinase 1 phosphorylates and stabilizes KLF4 to promote tumorigenesis in nasopharyngeal carcinoma.
Polo-like kinase 3, hypoxic responses, and tumorigenesis.
Regulatory functional territory of PLK-1 and their substrates beyond mitosis.
Selectivity-determining residues in Plk1.
Splicing Regulator p54nrb /NONO Enhances Carcinogenesis Through Oncogenic Isoform Switch of BIN1 in Hepatocellular Carcinoma.
The balance of Polo-like kinase 1 in tumorigenesis.
The deregulated promoter methylation of the Polo-like kinases as a potential biomarker in hematological malignancies.
The MicroRNA3686 Inhibits the Proliferation of Pancreas Carcinoma Cell Line by Targeting the Polo-Like Kinase 1.
The role of polo-like kinase 1 in carcinogenesis: cause or consequence?
Theoretical model of treatment strategies for clear cell carcinoma of the ovary: Focus on perspectives.
Thymoquinone blocks pSer/pThr recognition by Plk1 Polo-box domain as a phosphate mimic.
[Enhancive Effect of PLK1 Gene Silencing onSensitivity of K562/A02 Cells to Adriamycin.]
 p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
Carcinoma
A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma.
Antitumoral effect of PLK-1-inhibitor BI2536 in combination with cisplatin and docetaxel in squamous cell carcinoma cell lines of the head and neck.
Association of Polo-Like Kinase 3 and PhosphoT273 Caspase 8 Levels With Disease-Related Outcomes Among Cervical Squamous Cell Carcinoma Patients Treated With Chemoradiation and Brachytherapy.
BUBR1 overexpression predicts disease-specific survival after nephroureterectomy in patients with upper tract urothelial carcinoma.
Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer.
Effects of marine sponge extracts on mitogen-activated protein kinase (MAPK/ERK(1,2)) activity in SW-13 human adrenal carcinoma cells.
Evaluation of Polo-like kinase 1 as a potential therapeutic target in Merkel cell carcinoma.
Expression of polo-like kinase 1 (PLK1) protein predicts the survival of patients with gastric carcinoma.
High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.
Immunohistochemical expression of polo-like kinase 1 in oral squamous cell carcinoma and oral submucous fibrosis.
In vitro targeting of Polo-like kinase 1 in bladder carcinoma: comparative effects of four potent inhibitors.
Molecular Targets of Genistein and Its Related Flavonoids to Exert Anticancer Effects.
Oncogenic effect of Polo-like kinase 1 expression in human gastric carcinomas.
Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of Polo-like kinase-1.
PLK1 Is transcriptionally activated by NF-?B during cell detachment and enhances anoikis resistance through inhibiting ?-catenin degradation in esophageal squamous cell carcinoma.
PLK1 promotes epithelial-mesenchymal transition and metastasis of gastric carcinoma cells.
Polo-like kinase 1 as a promising diagnostic biomarker and potential therapeutic target for hepatocellular carcinoma.
Polo-like kinase 1 expression is suppressed by CCAAT/enhancer-binding protein ? to mediate colon carcinoma cell differentiation and apoptosis.
Polo-like kinase 1 overexpression is an early event in the progression of papillary carcinoma.
Polo-like kinase 3 and phosphoT273 caspase-8 are associated with improved local tumor control and survival in patients with anal carcinoma treated with concomitant chemoradiotherapy.
Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma.
Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck.
Prognostic significance of polo-like kinase expression in esophageal carcinoma.
PSK, a novel STE20-like kinase derived from prostatic carcinoma that activates the c-Jun N-terminal kinase mitogen-activated protein kinase pathway and regulates actin cytoskeletal organization.
RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells.
Targeted inhibition of Polo-like kinase 1 by a novel small-molecule inhibitor induces mitotic catastrophe and apoptosis in human bladder cancer cells.
Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.
The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis.
The expression of PLK-1 in cervical carcinoma: a possible target for enhancing chemosensitivity.
The MicroRNA3686 Inhibits the Proliferation of Pancreas Carcinoma Cell Line by Targeting the Polo-Like Kinase 1.
Carcinoma, Ehrlich Tumor
Effect of protein kinase inhibitors on activity of mammalian small heat-shock protein (HSP25) kinase.
Carcinoma, Hepatocellular
A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment.
Aberrant Polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma.
An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma.
Comprehensive and Integrative Analysis Reveals the Diagnostic, Clinicopathological and Prognostic Significance of Polo-Like Kinase 1 in Hepatocellular Carcinoma.
Discovery of methyl 3-((2-((1-(dimethylglycyl)-5-methoxyindolin-6-yl)amino)-5-(trifluoro-methyl) pyrimidin-4-yl)amino)thiophene-2-carboxylate as a potent and selective polo-like kinase 1 (PLK1) inhibitor for combating hepatocellular carcinoma.
Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis.
Dual targeting of Polo-like kinase 1 and baculoviral inhibitor of apoptosis repeat-containing 5 in TP53-mutated hepatocellular carcinoma.
High expression of polo-like kinase 1 is associated with early development of hepatocellular carcinoma.
Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
Intravenous liposomal delivery of the short hairpin RNAs against Plk1 controls the growth of established human hepatocellular carcinoma.
Polo-like kinase 1 as a promising diagnostic biomarker and potential therapeutic target for hepatocellular carcinoma.
Polo-like kinase 1 contributes to the tumorigenicity of BEL-7402 hepatoma cells via regulation of Survivin expression.
Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.
Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
[Expression and prognostic value of Polo-like kinase 1, E-cadherin in the patients with hepatocellular carcinoma]
Carcinoma, Medullary
Polo-like kinase 1 expression in medullary carcinoma of the thyroid: its relationship with clinicopathological features.
Carcinoma, Merkel Cell
Evaluation of Polo-like kinase 1 as a potential therapeutic target in Merkel cell carcinoma.
Carcinoma, Non-Small-Cell Lung
Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells.
Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitor.
Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536.
Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1.
Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer.
PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer.
Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells.
Polo-like kinase 4 correlates with greater tumor size, lymph node metastasis and confers poor survival in non-small cell lung cancer.
Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer.
Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status.
Sepantronium is a DNA damaging agent that synergizes with PLK1 inhibitor volasertib.
Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer.
The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial.
Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia.
Carcinoma, Ovarian Epithelial
Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer.
Carcinoma, Papillary
Polo-like kinase 1 overexpression is an early event in the progression of papillary carcinoma.
Carcinoma, Squamous Cell
Antitumoral effect of PLK-1-inhibitor BI2536 in combination with cisplatin and docetaxel in squamous cell carcinoma cell lines of the head and neck.
Association of Polo-Like Kinase 3 and PhosphoT273 Caspase 8 Levels With Disease-Related Outcomes Among Cervical Squamous Cell Carcinoma Patients Treated With Chemoradiation and Brachytherapy.
Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck.
Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.
The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis.
Cataract
Histone acetyltransferase and Polo-like kinase 3 inhibitors prevent rat galactose-induced cataract.
Cholangiocarcinoma
Bcl-2 degradation is an additional pro-apoptotic effect of polo-like kinase inhibition in cholangiocarcinoma cells.
Polo-like kinase 1 inhibition as a new therapeutic modality in therapy of cholangiocarcinoma.
Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma.
Polo-like kinase 3 is associated with improved overall survival in cholangiocarcinoma.
Therapeutic Rationale to Target Highly Expressed Aurora kinase A Conferring Poor Prognosis in Cholangiocarcinoma.
Colonic Neoplasms
Aberrant Wnt/beta-catenin signaling can induce chromosomal instability in colon cancer.
Apoptosis induction with polo-like kinase-1 antisense phosphorothioate oligodeoxynucleotide of colon cancer cell line SW480.
Polo-like kinase 1 expression is a prognostic factor in human colon cancer.
Preferential Killing of Tetraploid Colon Cancer Cells by Targeting the Mitotic Kinase PLK1.
Colorectal Neoplasms
Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.
Clinicopathological and prognostic implications of polo-like kinase 1 expression in colorectal cancer: A systematic review and meta-analysis.
Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
Forkhead box D1 promotes proliferation and suppresses apoptosis via regulating polo-like kinase 2 in colorectal cancer.
PLK-1 Expression is Associated with Histopathological Response to Neoadjuvant Therapy of Hepatic Metastasis of Colorectal Carcinoma.
Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers.
Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells.
Polo-like kinase 2 promotes chemoresistance and predicts limited survival benefit from adjuvant chemotherapy in colorectal cancer.
Polo-like kinase 3 inhibits glucose metabolism in colorectal cancer by targeting HSP90/STAT3/HK2 signaling.
Tazarotene-induced gene 1 interacts with Polo-like kinase 2 and inhibits cell proliferation in HCT116 colorectal cancer cells.
Upregulated Polo-Like Kinase 1 Expression Correlates with Inferior Survival Outcomes in Rectal Cancer.
[Influence of silencing Polo-like kinase 1 on migration and invasion of colorectal cancer cells].
Cystadenoma
Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
DNA Repair-Deficiency Disorders
High expression of polo-like kinase 1 is associated with TP53 inactivation, DNA repair deficiency, and worse prognosis in ER positive Her2 negative breast cancer.
Endometrial Neoplasms
Polo-like kinase (PLK) expression in endometrial carcinoma.
Endometriosis
High expression levels of cyclin B1 and Polo-like kinase 1 in ectopic endometrial cells associated with abnormal cell cycle regulation of endometriosis.
Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
Esophageal Neoplasms
Elucidation of PLK1 Linked Biomarkers in Oesophageal Cancer Cell Lines: A Step Towards Novel Signaling Pathways by p53 and PLK1- Linked Functions Crosstalk.
Moscatilin Inhibits Growth of Human Esophageal Cancer Xenograft and Sensitizes Cancer Cells to Radiotherapy.
Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593* in esophageal cancer.
Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells.
Esophageal Squamous Cell Carcinoma
A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma.
PLK1 Is transcriptionally activated by NF-?B during cell detachment and enhances anoikis resistance through inhibiting ?-catenin degradation in esophageal squamous cell carcinoma.
Glioblastoma
A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1.
Effects of phospholipase Cgamma on Polo-like kinase 1 expression in human glioma cells.
GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM).
Increased human polo-like kinase-1 expression in gliomas.
Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation.
Inhibition of polo-like kinase 1 induces cell cycle arrest and sensitizes glioblastoma cells to ionizing radiation.
Multiple forms of protein kinase from normal human brain and glioblastoma.
Polo-Like Kinase 1 (PLK1) Inhibition Kills Glioblastoma Multiforme Brain Tumour Cells in Part Through Loss of SOX2 and Delays Tumour Progression in Mice.
Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma.
The enhancement of siPLK1 penetration across BBB and its anti glioblastoma activity in vivo by magnet and transferrin co-modified nanoparticle.
Glioma
Circular RNA ZNF609 promotes the malignant progression of glioma by regulating miR-1224-3p/PLK1 signaling.
Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma.
Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma.
Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC.
Effects of phospholipase Cgamma on Polo-like kinase 1 expression in human glioma cells.
Increased human polo-like kinase-1 expression in gliomas.
Knocking down of Polo-like kinase 2 inhibits cell proliferation and induced cell apoptosis in human glioma cells.
Long noncoding RNA ENST00000413528 sponges microRNA-593-5p to modulate human glioma growth via polo-like kinase 1.
Protein kinase translocation following beta-adrenergic receptor activation in C6 glioma cells.
The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells.
Head and Neck Neoplasms
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI).
Hematologic Neoplasms
A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies.
c-Src activation through a TrkA and c-Src interaction is essential for cell proliferation and hematological malignancies.
Epigenetic inactivation implies a tumor suppressor function in hematologic malignancies for Polo-like kinase 2 but not Polo-like kinase 3.
Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells.
Polo-like kinase inhibitors in hematologic malignancies.
Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines.
Hepatitis B
Polo-like kinase 1 activated by the hepatitis B virus X protein attenuates both the DNA damage checkpoint and DNA repair resulting in partial polyploidy.
Polo-like kinase 1 inhibition suppresses hepatitis B virus X protein-induced transformation in an in vitro model of liver cancer progression.
Polo-like-kinase 1 is a proviral host-factor for hepatitis B virus replication.
[Hepatitis B virus X protein-regulated expression of Plk1].
Hepatitis C
Polo-like kinase 1 is involved in hepatitis C virus replication by hyperphosphorylating NS5A.
Hypogonadism
Male Hypogonadism and Germ Cell Loss Caused by a Mutation in Polo-Like Kinase 4.
Infections
Clinical Significance of Polo-Like Kinase 4 as a Marker for Advanced Tumor Stage and Dismal Prognosis in Patients With Surgical Gastric Cancer.
In vivo and in vitro phosphorylation of DNA-dependent RNA polymerase of Escherichia coli by bacteriophage-T7-induced protein kinase.
Inhibition of polo-like kinase 1 (PLK1) facilitates reactivation of gamma-herpesviruses and their elimination.
Inhibition of Polo-like kinase 1 (PLK1) facilitates the elimination of HIV-1 viral reservoirs in CD4+ T cells ex vivo.
Protein kinase of bacteriophage T7. 1. Purification.
Temporal SILAC-based quantitative proteomics identifies host factors involved in chikungunya virus replication.
[PLK1 Expression in Mantle Cell Lymphoma and Its Clinical Significance].
Infertility, Female
Female infertility in PDE3A(-/-) mice: polo-like kinase 1 (Plk1) may be a target of protein kinase A (PKA) and involved in meiotic arrest of oocytes from PDE3A(-/-) mice.
Insulin Resistance
Insulin Resistance Promotes Parkinson's Disease through Aberrant Expression of ?-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling.
Kidney Neoplasms
Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells.
Leukemia
A systems biology approach for elucidating the interaction of curcumin with Fanconi anemia FANC G protein and the key disease targets of leukemia.
Beta-hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1).
c-Src activation through a TrkA and c-Src interaction is essential for cell proliferation and hematological malignancies.
Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells.
Enhanced polo-like kinase 1 expression in myelodysplastic syndromes.
PLK-1 Expression is Associated with Histopathological Response to Neoadjuvant Therapy of Hepatic Metastasis of Colorectal Carcinoma.
PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
Polo-like kinase-1 as novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of siRNA and the Polo-like kinase-1 targeting drug BI 2536.
Polo-like kinases in AML.
Targeted Polo-like Kinase Inhibition Combined With Aurora Kinase Inhibition in Pediatric Acute Leukemia Cells.
Targeting polo-like kinase 1 suppresses essential functions of alloreactive T cells.
TrkC promotes survival and growth of leukemia cells through Akt-mTOR-Dependent Up-Regulation of PLK-1 and Twist-1.
[Expression of plk-1 gene in acute leukemia patients and its significance]
Leukemia, Mast-Cell
Polo-like kinase-1 as novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of siRNA and the Polo-like kinase-1 targeting drug BI 2536.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage.
Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Leukemia, Myeloid
Polo-like kinase-1 as novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of siRNA and the Polo-like kinase-1 targeting drug BI 2536.
Leukemia, Myeloid, Acute
A phase 1b study of onvansertib, a novel oral PLK1 inhibitor, in combination therapy for patients with relapsed or refractory acute myeloid leukemia.
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial.
Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia.
Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells.
Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions.
Polo-like kinase inhibition as a therapeutic target in acute myeloid leukemia.
Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia.
Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
Radotinib inhibits mitosis entry in acute myeloid leukemia cells via suppression of Aurora kinase A expression.
RNAi prodrugs decrease elevated mRNA levels of Polo-like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients.
Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo.
Targeted therapy of acute myeloid leukemia.
Targeting polo-like kinase 1 in acute myeloid leukemia.
Liver Cirrhosis
Polo-like kinase 1 as a promising diagnostic biomarker and potential therapeutic target for hepatocellular carcinoma.
Liver Neoplasms
Escheriosome-mediated cytosolic delivery of PLK1-specific siRNA: potential in treatment of liver cancer in BALB/c mice.
Polo-like kinase 1 inhibition suppresses hepatitis B virus X protein-induced transformation in an in vitro model of liver cancer progression.
Lung Neoplasms
Absolute quantification of protein and post-translational modification abundance with stable isotope-labeled synthetic peptides.
Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer.
An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).
Cell cycle inhibitors for the treatment of NSCLC.
Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells.
Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitor.
Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536.
Effect of antisense RNA targeting polo-like kinase 1 on cell cycle and proliferation in A549 cells.
Effect of antisense RNA targeting Polo-like kinase 1 on cell growth in A549 lung cancer cells.
Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
Inhibiting polo-like kinase 1 enhances radiosensitization via modulating DNA repair proteins in non-small-cell lung cancer.
Inhibition of Plk1 and Pin1 by 5'-nitro-indirubinoxime suppresses human lung cancer cells.
In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1.
Non-canonical cMet regulation by vimentin mediates Plk1 inhibitor-induced apoptosis.
Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer.
pH-responsive hybrid nanoparticle with enhanced dissociation characteristic for siRNA delivery.
PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer.
Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.
Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells.
Polo-like kinase 4 correlates with greater tumor size, lymph node metastasis and confers poor survival in non-small cell lung cancer.
Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers.
Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer.
Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status.
RNA interference against polo-like kinase-1 in advanced non-small cell lung cancers.
Sepantronium is a DNA damaging agent that synergizes with PLK1 inhibitor volasertib.
Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer.
The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial.
Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia.
[Effect of antisense RNA targeting Polo-like kinase 1 on cell cycle of lung cancer cell line A549]
Lymphatic Metastasis
Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor.
Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer.
Polo-like kinase 4 correlates with greater tumor size, lymph node metastasis and confers poor survival in non-small cell lung cancer.
Lymphoma
Absence of tumor-specific over-expression of Polo-like kinase 1 (Plk1) in major non-Hodgkin lymphoma and relatively low expression of Plk1 in nasal NK/T cell lymphoma.
Altered regulation of cyclic AMP-dependent protein kinase in a mouse lymphoma cell line.
Enhanced polo-like kinase 1 expression in myelodysplastic syndromes.
Expression of PLK1 and survivin in non-Hodgkinos lymphoma treated with CHOP.
Expression of Polo-Like Kinase (PLK1) in non-Hodgkin's lymphomas.
Kinase Inhibitor Indole Derivatives as Anticancer Agents: A Patent Review.
PLK1: a promising and previously unexplored target in double-hit lymphoma.
Polo-like kinase 1 (PLK1) expression is associated with cell proliferative activity and cdc2 expression in malignant lymphoma of the thyroid.
Polo-like kinase 1 is essential to DNA damage recovery.
Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions.
Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas.
Resveratrol activates DNA damage response through inhibition of polo-like kinase 1 (PLK1) in natural killer/T cell lymphoma.
Subunit interaction in cyclic AMP-dependent protein kinase of mutant lymphoma cells.
Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
Lymphoma, B-Cell
Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma.
PLK1: a promising and previously unexplored target in double-hit lymphoma.
Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
The contribution of MYC and PLK1 expression to proliferative capacity in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma.
Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
Lymphoma, Mantle-Cell
Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
Lymphoma, Non-Hodgkin
Absence of tumor-specific over-expression of Polo-like kinase 1 (Plk1) in major non-Hodgkin lymphoma and relatively low expression of Plk1 in nasal NK/T cell lymphoma.
Polo-like kinase 1 as a new target for non-Hodgkin's lymphoma treatment.
The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin's lymphoma: A Phase I, open-label, single dose-escalation study.
Lymphoma, T-Cell, Cutaneous
Polo-like kinase 1 (Plk1) in cutaneous T-cell lymphoma.
Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs) and its down-regulation promotes cell cycle arrest and apoptosis.
Lymphoproliferative Disorders
The role of aurora A and polo-like kinases in high-risk lymphomas.
Mastocytosis, Systemic
Polo-like kinase-1 as novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of siRNA and the Polo-like kinase-1 targeting drug BI 2536.
Medulloblastoma
A Regulatory Loop of FBXW7-MYC-PLK1 Controls Tumorigenesis of MYC-Driven Medulloblastoma.
Comparative Effects of Polo-Like Kinase 1 Inhibitors as Monotherapy and in Combination with Current Treatments for Medulloblastoma.
Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma.
Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase PLK1 as a molecular target in high-risk children.
Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells.
The polo-like kinase 4 gene (PLK4) is overexpressed in pediatric medulloblastoma.
Melanoma
Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.
Downregulation of Polo-like kinase-1 (PLK-1) expression is associated with poor clinical outcome in uveal melanoma patients.
Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease.
In Vivo ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma.
Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
Large-Scale Label-Free Comparative Proteomics Analysis of Polo-Like Kinase 1 Inhibition via the Small-Molecule Inhibitor BI 6727 (Volasertib) in BRAF(V600E) Mutant Melanoma Cells.
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI).
Multiple agminated Spitz nevi arising on a café au lait macule: review of the literature with contribution of another case.
Playing Polo-Like Kinase in NRAS-Mutant Melanoma.
PLK1 and NOTCH Positively Correlate in Melanoma and Their Combined Inhibition Results in Synergistic Modulations of Key Melanoma Pathways.
Polo-like kinase 1 is a potential therapeutic target in human melanoma.
Polo-like kinase-1 immunoreactivity is associated with metastases in cutaneous melanoma.
Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
Targeted Depletion of Polo-Like Kinase (Plk) 1 Through Lentiviral shRNA or a Small-Molecule Inhibitor Causes Mitotic Catastrophe and Induction of Apoptosis in Human Melanoma Cells.
Targeted knockdown of polo-like kinase 1 alters metabolic regulation in melanoma.
The role of polo-like kinase 3 in the response of BRAF-mutant cells to targeted anticancer therapies.
Mesothelioma, Malignant
A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro.
Microcephaly
Microduplication of the ARID1A gene causes intellectual disability with recognizable syndromic features.
Overexpression of the PLK4 Gene as a Novel Strategy for the Treatment of Autosomal Recessive Microcephaly by Improving Centrosomal Dysfunction.
Mouth Neoplasms
ER maleate is a novel anticancer agent in oral cancer: Implications for cancer therapy.
Kinome-Wide Screening with Small Interfering RNA Identified Polo-like Kinase 1 as a Key Regulator of Proliferation in Oral Cancer Cells.
Multiple Myeloma
Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.
Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation.
Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions.
The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma.
Mumps
Mumps Virus Nucleoprotein Enhances Phosphorylation of the Phosphoprotein by Polo-Like Kinase 1.
Myelodysplastic Syndromes
Enhanced polo-like kinase 1 expression in myelodysplastic syndromes.
Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions.
Nasopharyngeal Carcinoma
Polo-Like Kinase 1 phosphorylates and stabilizes KLF4 to promote tumorigenesis in nasopharyngeal carcinoma.
Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.
Up-regulation of Polo-like Kinase 1 in nasopharyngeal carcinoma tissues: a comprehensive investigation based on RNA-sequencing, gene chips, and in-house tissue arrays.
Neoplasm Metastasis
Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer.
Anticancer effects on TACC3 by treatment of paclitaxel in HPV-18 positive cervical carcinoma cells.
Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy.
Clinical Significance of Polo-Like Kinase 4 as a Marker for Advanced Tumor Stage and Dismal Prognosis in Patients With Surgical Gastric Cancer.
Down-regulation of Polo-like kinase 4 (PLK4) induces G1 arrest via activation of the p38/p53/p21 signaling pathway in bladder cancer.
Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer.
Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis.
High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.
Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor.
Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer.
Phosphorylation of human enhancer filamentation 1 (HEF1) stimulates interaction with Polo-like kinase 1 leading to HEF1 localization to focal adhesions.
PLK-1 Expression is Associated with Histopathological Response to Neoadjuvant Therapy of Hepatic Metastasis of Colorectal Carcinoma.
PLK1 promotes epithelial-mesenchymal transition and metastasis of gastric carcinoma cells.
Polo-like kinase 1 is a potential therapeutic target in human melanoma.
Polo-like kinase 3 is associated with poor prognosis and regulates proliferation and metastasis in prostate cancer.
Polo-like kinase 4 correlates with greater tumor size, lymph node metastasis and confers poor survival in non-small cell lung cancer.
Polo-like kinase-1 immunoreactivity is associated with metastases in cutaneous melanoma.
Regulation of E2F Transcription Factor 3 by microRNA-152 Modulates Gastric Cancer Invasion and Metastasis.
Role of NEK2A in Human Cancer and Its Therapeutic Potentials.
The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor Metastasis.
Wnt5a-induced docking of Plk1 on HEF1 promotes HEF1 translocation and tumorigenesis.
Neoplasm, Residual
Promoting tumor penetration of nanoparticles for cancer stem cell therapy by TGF-? signaling pathway inhibition.
Neoplasms
A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment.
A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer.
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS.
A fluorescence polarization assay for the discovery of inhibitors of the polo-box domain of polo-like kinase 1.
A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.
A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1.
A novel anti-tumor inhibitor identified by virtual screen with PLK1 structure and zebrafish assay.
A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.
A phase I study of volasertib combined with afatinib, in advanced solid tumors.
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.
A Regulatory Loop of FBXW7-MYC-PLK1 Controls Tumorigenesis of MYC-Driven Medulloblastoma.
A ribonucleoprotein octamer for targeted siRNA delivery.
A Yeast Synthetic Dosage Lethal Screen Identifies a Conserved Interaction between PLK1 and CKS1B Affecting Cancer Cell Viability.
Absence of polo-like kinase 3 in mice stabilizes Cdc25A after DNA damage but is not sufficient to produce tumors.
An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies.
An oncoinformatics study to predict the inhibitory potential of recent FDA-approved anti-cancer drugs against human Polo-like kinase 1 enzyme: a step towards dual-target cancer medication.
An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.
An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer.
Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).
Anticancer effects of radiation therapy combined with Polo-Like Kinase 4 (PLK4) inhibitor CFI-400945 in triple negative breast cancer.
Anticancer effects on TACC3 by treatment of paclitaxel in HPV-18 positive cervical carcinoma cells.
Antiproliferative in vitro effects of BI 2536-mediated PLK1 inhibition on cervical adenocarcinoma cells.
Apoptotic effects of genistein, biochanin-A and apigenin on LNCaP and PC-3 cells by p21 through transcriptional inhibition of polo-like kinase-1.
Application of Post Solid-Phase Oxime Ligation to Fine-Tune Peptide-Protein Interactions.
Aurora-A and hBora join the game of Polo.
Balancing polymer hydrophobicity for ligand presentation and siRNA delivery in dual function CXCR4 inhibiting polyplexes.
Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy.
BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity.
BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments.
BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1.
Binding of the anticancer drug BI-2536 to human serum albumin. A spectroscopic and theoretical study.
Biological impact of freezing Plk1 in its inactive conformation in cancer cells.
Branched Antisense and siRNA Co-Assembled Nanoplatform for Combined Gene Silencing and Tumor Therapy.
Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1.
Cancer Osaka thyroid (Cot) phosphorylates Polo-like kinase (PLK1) at Ser137 but not at Thr210.
Cell biology. Reversible centriole depletion with an inhibitor of Polo-like kinase 4.
Cell type-- dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines.
Characterization of protein tyrosine kinase activity in murine Leydig tumor cells.
Click modified amphiphilic graft copolymeric micelles of poly(styrene-alt-maleic anhydride) for combinatorial delivery of doxorubicin and plk-1 siRNA in cancer therapy.
Clinical Significance of Polo-Like Kinase 4 as a Marker for Advanced Tumor Stage and Dismal Prognosis in Patients With Surgical Gastric Cancer.
Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
Combination of PI3K/Akt Pathway Inhibition and Plk1 Depletion Can Enhance Chemosensitivity to Gemcitabine in Pancreatic Carcinoma.
Combined Gene Expression Profiling and RNAi Screening in Clear Cell Renal Cell Carcinoma Identify PLK1 and Other Therapeutic Kinase Targets.
Computational analysis of phosphopeptide binding to the polo-box domain of the mitotic kinase PLK1 using molecular dynamics simulation.
Conditional inhibition of cancer cell proliferation by tetracycline-responsive, H1 promoter-driven silencing of PLK1.
Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice.
Correction: Novel Oncolytic Adenovirus Selectively Targets Tumor-Associated Polo-Like Kinase 1 and Tumor Cell Viability.
Cotargeting Polo-Like Kinase 1 and the Wnt/?-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer.
Current assessment of polo-like kinases as anti-tumor drug targets.
Current clinical trials with polo-like kinase 1 inhibitors in solid tumors.
Deciphering the performance of polo-like kinase 1 in triple-negative breast cancer progression according to the centromere protein U-phosphorylation pathway.
Decreased KPNB1 Expression is Induced by PLK1 Inhibition and Leads to Apoptosis in Lung Adenocarcinoma.
Defeat Mutant KRAS with Synthetic Lethality.
Design and evaluation of ionizable peptide amphiphiles for siRNA delivery.
Design and Synthesis of a Novel PLK1 Inhibitor Scaffold Using a Hybridized 3D-QSAR Model.
Design of Cationic Multiwalled Carbon Nanotubes as Efficient siRNA Vectors for Lung Cancer Xenograft Eradication.
Design of Peptidomimetic Functionalized Cholesterol Based Lipid Nanoparticles for Efficient Delivery of Therapeutic Nucleic Acids.
Design, synthesis, and biological evaluation of novel highly selective polo-like kinase 2 inhibitors based on the tetrahydropteridin chemical scaffold.
Designed inhibitor for nuclear localization signal of polo-like kinase 1 induces mitotic arrest.
Detection and destruction of HER2-positive cancer cells by Ultra Quenchbody-siRNA complex.
Development of a Novel Cell-Permeable Protein-Protein Interaction Inhibitor for the Polo-box Domain of Polo-like Kinase 1.
Development of a Polo-like Kinase-1 Polo-Box Domain Inhibitor as a Tumor Growth Suppressor in Mice Models.
Development of Bifunctional Inhibitors of Polo-Like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain.
Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy.
Discovery of Novel Polo-Like Kinase 1 Polo-Box Domain Inhibitors to Induce Mitotic Arrest in Tumor Cells.
Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001.
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations.
DITMD-induced mitotic defects and apoptosis in tumor cells by blocking the polo-box domain-dependent functions of polo-like kinase 1.
Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function.
Down-regulation of Polo-like kinase 4 (PLK4) induces G1 arrest via activation of the p38/p53/p21 signaling pathway in bladder cancer.
Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells.
Downregulation of PLK-1 expression in kaempferol-induced apoptosis of MCF-7 cells.
Downregulation of Polo-like kinase-1 (PLK-1) expression is associated with poor clinical outcome in uveal melanoma patients.
Dynamic and multi-pharmacophore modeling for designing polo-box domain inhibitors.
Effect of AKT3 expression on MYC- and caspase-8-dependent apoptosis caused by polo-like kinase inhibitors in HCT 116 cells.
Effect of Cationic Lipid Type in Folate-PEG-Modified Cationic Liposomes on Folate Receptor-Mediated siRNA Transfection in Tumor Cells.
Effect of protein kinase inhibitors on activity of mammalian small heat-shock protein (HSP25) kinase.
Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells.
Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
Efficient internalization of the polo-box of polo-like kinase 1 fused to an Antennapedia peptide results in inhibition of cancer cell proliferation.
Elucidation of PLK1 Linked Biomarkers in Oesophageal Cancer Cell Lines: A Step Towards Novel Signaling Pathways by p53 and PLK1- Linked Functions Crosstalk.
Enabling and disabling Polo-like kinase 1 inhibition through chemical genetics.
Engineering Human Epidermal Growth Receptor 2-Targeting Hepatitis B Virus Core Nanoparticles for siRNA Delivery in Vitro and in Vivo.
Enhanced polo-like kinase 1 expression in myelodysplastic syndromes.
Enhancing Gene-Knockdown Efficiency of Poly(N-isopropylacrylamide) Nanogels.
Epigenetic inactivation implies a tumor suppressor function in hematologic malignancies for Polo-like kinase 2 but not Polo-like kinase 3.
ER maleate is a novel anticancer agent in oral cancer: Implications for cancer therapy.
Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer.
Evaluation of
Exploring the binding nature of pyrrolidine pocket-dependent interactions in the polo-box domain of polo-like kinase 1.
Fate of primary cells at the G?/S boundary after polo-like kinase 1 inhibition by SBE13.
Folate-Mediated Targeted Delivery of siPLK1 by Leucine-Bearing Polyethylenimine.
Formation of extra centrosomal structures is dependent on beta-catenin.
Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis.
Freezing Polo in its sleep: targeting the inactive conformation of Polo-like kinase 1 in cancer cells.
Future prospect of RNA interference for cancer therapies.
Gene regulation with carbon-based siRNA conjugates for cancer therapy.
Glucose-linked sub-50-nm unimer polyion complex-assembled gold nanoparticles for targeted siRNA delivery to glucose transporter 1-overexpressing breast cancer stem-like cells.
GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM).
Helicobacter pylori promotes gastric epithelial cell survival through the PLK1/PI3K/Akt pathway.
High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.
High levels of polo-like kinase 1 and phosphorylated translationally controlled tumor protein indicate poor prognosis in neuroblastomas.
Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1.
Identification of a high affinity selective inhibitor of Polo-like kinase 1 for cancer chemotherapy by computational approach.
Identification of a New Heterocyclic Scaffold for Inhibitors of the Polo-Box Domain of Polo-like Kinase 1.
Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain.
Identification of a Polo-like Kinase 4-Dependent Pathway for De Novo Centriole Formation.
Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
Identification of novel polo-like kinase 1 inhibitors by a hybrid virtual screening.
Identification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assay.
Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs.
Immunohistochemical expression of polo-like kinase 1 in oral squamous cell carcinoma and oral submucous fibrosis.
Impact Of Plk-1 Silencing On Endothelial Cells And Cancer Cells Of Diverse Histological Origin.
In Vitro and In Vivo Tumor-Targeting siRNA Delivery Using Folate-PEG-appended Dendrimer (G4)/?-Cyclodextrin Conjugates.
In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells.
In-silico design and synthesis of N9-substituted ?-Carbolines as PLK-1 inhibitors and their in-vitro/in-vivo tumor suppressing evaluation.
Induction of antitumor immunity using dendritic cells electroporated with Polo-like kinase 1 (Plk1) mRNA in murine tumor models.
Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells.
Inhibition of dynamin by dynole 34-2 induces cell death following cytokinesis failure in cancer cells.
Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer.
Inhibition of PLK4 might enhance the anti-tumour effect of bortezomib on glioblastoma via PTEN/PI3K/AKT/mTOR signalling pathway.
Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
Inhibition of polo-like kinase 1 induces cell cycle arrest and sensitizes glioblastoma cells to ionizing radiation.
Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain.
Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms.
Inhibition of Suicidal Erythrocyte Death by Volasertib.
Inhibitors of the Polo-Box Domain of Polo-like Kinase 1.
Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
Integrated bioinformatics analysis reveals CDK1 and PLK1 as potential therapeutic targets of lung adenocarcinoma.
Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma.
Involvement of Polo-like kinase 1 (Plk1) in quiescence regulation of cancer stem-like cells of the gastric cancer cell lines.
In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
In vivo tumor imaging using polo-box domain of polo-like kinase 1 targeted peptide.
Ionizing radiation inhibits the PLK cell cycle gene in a G2 checkpoint-dependent manner.
Kinome inhibition reveals a role for polo-like kinase 1 in targeting post-transcriptional control in cancer.
KRAS Cold Turkey: Using microRNAs to target KRAS-addicted cancer.
Liaisons between survivin and PLK1 during cell division and cell death.
Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1).
Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
Low dietary folate initiates intestinal tumors in mice, with altered expression of G2-M checkpoint regulators polo-like kinase 1 and cell division cycle 25c.
Luteolin-Fabricated ZnO Nanostructures Showed PLK-1 Mediated Anti-Breast Cancer Activity.
Matrix metalloproteinase 2-responsive micelle for siRNA delivery.
MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate.
Mechanisms of omega-3 fatty acid-induced growth inhibition in MDA-MB-231 human breast cancer cells.
MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1.
miR-296-5p suppresses cell viability by directly targeting PLK1 in non-small cell lung cancer.
Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer.
Modular Plasmonic Nanocarriers for Efficient and Targeted Delivery of Cancer-Therapeutic siRNA.
Modulating Polo-Like Kinase 1 as a Means for Cancer Chemoprevention.
Molecular alterations after Polo-like kinase 1 mRNA suppression versus pharmacologic inhibition in cancer cells.
Molecular and enzoinformatics perspectives of targeting Polo-like kinase 1 in cancer therapy.
Molecular interactions of polo-like kinase 1 in human cancers.
Molecular targeting of the oncoprotein PLK1 in pediatric acute myeloid leukemia: RO3280, a novel PLK1 inhibitor, induces apoptosis in leukemia cells.
Molecular Targets of Genistein and Its Related Flavonoids to Exert Anticancer Effects.
Monitoring of changes in lipid profiles during PLK1 knockdown in cancer cells using DESI MS.
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI).
Multifunctional polyion complex micelle featuring enhanced stability, targetability, and endosome escapability for systemic siRNA delivery to subcutaneous model of lung cancer.
Multiplexed random peptide library and phospho-specific antibodies facilitate human polo-like kinase 1 inhibitor screen.
Network Pharmacological Analysis through a Bioinformatics Approach of Novel NSC765600 and NSC765691 Compounds as Potential Inhibitors of CCND1/CDK4/PLK1/CD44 in Cancer Types.
New Inhibitors of Polo-like Kinase 1 Function and Their Emerging Role in Attenuating Tumor Growth in Systemic Malignancies.
NMS-P937, an orally available, specific, small molecule Polo-Like Kinase 1 inhibitor with antitumor activity in solid and haematological malignancies.
Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide.
Normal cells, but not cancer cells, survive severe plk1 depletion.
Novel biomarker for hepatocellular carcinoma: high tumoral PLK-4 expression is associated with better prognosis in patients without microvascular invasion.
Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability.
Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor.
Nuclear pore protein NUP88 activates anaphase-promoting complex to promote aneuploidy.
OCT4B1 Promoted EMT and Regulated the Self-Renewal of CSCs in CRC: Effects Associated with the Balance of miR-8064/PLK1.
Oncogenic regulators and substrates of the anaphase promoting complex/cyclosome are frequently overexpressed in malignant tumors.
Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of Polo-like kinase-1.
Overexpression of human ABCB1 in cancer cells leads to reduced activity of GSK461364, a specific inhibitor of polo-like kinase 1.
Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer.
p53 and its downstream proteins as molecular targets of cancer.
pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1.
Pharmacoinformatics approach for the identification of Polo-like kinase-1 inhibitors from natural sources as anti-cancer agents.
Phase 1 study of rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.
Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.
Phase I study of GSK461364, a specific and competitive Polo-like Kinase 1 (PLK1) inhibitor in patients with advanced solid malignancies.
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies.
Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors.
Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity.
Phosphopeptides with improved cellular uptake properties as ligands for the polo-box domain of polo-like kinase 1.
Phosphorylation of human enhancer filamentation 1 (HEF1) stimulates interaction with Polo-like kinase 1 leading to HEF1 localization to focal adhesions.
PLK-1 Expression is Associated with Histopathological Response to Neoadjuvant Therapy of Hepatic Metastasis of Colorectal Carcinoma.
PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis.
Plk1 and CK2 act in concert to regulate Rad51 during DNA double strand break repair.
Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint.
PLK1 Induces Chromosomal Instability and Overrides Cell-Cycle Checkpoints to Drive Tumorigenesis.
Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer.
Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer.
Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.
Plk1 overexpression induces chromosomal instability and suppresses tumor development.
PLK1 promotes epithelial-mesenchymal transition and metastasis of gastric carcinoma cells.
Plk1 promotes the migration of human lung adenocarcinoma epithelial cells via STAT3 signaling.
Plk1 regulates contraction of postmitotic smooth muscle cells and is required for vascular homeostasis.
PLK1 signaling in breast cancer cells cooperates with estrogen receptor-dependent gene transcription.
Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma.
Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer.
Plk2 promotes tumor growth and inhibits apoptosis by targeting Fbxw7/Cyclin E in colorectal cancer.
Plk2 regulates mitotic spindle orientation and mammary gland development.
Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer.
Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells.
Polo-like kinase 1 (Plk1) in non-melanoma skin cancers.
Polo-Like Kinase 1 (PLK1) Inhibition Kills Glioblastoma Multiforme Brain Tumour Cells in Part Through Loss of SOX2 and Delays Tumour Progression in Mice.
Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells.
Polo-like kinase 1 (Plk1) overexpression enhances ionizing radiation-induced cancer formation in mice.
Polo-like kinase 1 (PLK1) signaling in cancer and beyond.
Polo-like kinase 1 as a therapeutic target for malignant peripheral nerve sheath tumors (MPNST) and schwannomas.
Polo-like kinase 1 as target for cancer therapy.
Polo-like kinase 1 contributes to the tumorigenicity of BEL-7402 hepatoma cells via regulation of Survivin expression.
Polo-like kinase 1 coordinates biosynthesis during cell cycle progression by directly activating pentose phosphate pathway.
Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation.
Polo-like kinase 1 in the life and death of cancer cells.
Polo-like kinase 1 induces epithelial-to-mesenchymal transition and promotes epithelial cell motility by activating CRAF/ERK signaling.
Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction.
Polo-like kinase 1 inhibition sensitizes neuroblastoma cells for vinca alkaloid-induced apoptosis.
Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.
Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells.
Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies.
Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53.
Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma.
Polo-like kinase 1 is essential for early embryonic development and tumor suppression.
Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells.
Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells.
Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades.
Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells.
Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593* in esophageal cancer.
Polo-like kinase 2 acting as a promoter in human tumor cells with an abundance of TAp73.
Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma.
Polo-like kinase 2, a novel ADAM17 signaling component, regulates tumor necrosis factor ? ectodomain shedding.
Polo-like kinase 3 and phosphoT273 caspase-8 are associated with improved local tumor control and survival in patients with anal carcinoma treated with concomitant chemoradiotherapy.
Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions.
Polo-like kinase 3 inhibits glucose metabolism in colorectal cancer by targeting HSP90/STAT3/HK2 signaling.
Polo-like kinase 3, hypoxic responses, and tumorigenesis.
Polo-like kinase 4 correlates with greater tumor size, lymph node metastasis and confers poor survival in non-small cell lung cancer.
Polo-like kinase 4 inhibition: a strategy for cancer therapy?
Polo-Like Kinase 4's Critical Role in Cancer Development and Strategies for Plk4-Targeted Therapy.
Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.
Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.
Polo-like kinase-1 as novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of siRNA and the Polo-like kinase-1 targeting drug BI 2536.
Polo-like kinase-1 immunoreactivity is associated with metastases in cutaneous melanoma.
Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73? in p53 mutant human epidermoid squamous carcinoma cells.
Polo-like kinase1, a new target for antisense tumor therapy.
Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer.
Polo-like kinases in AML.
Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas.
Poly-l-lysine Functionalized Large Pore Cubic Mesostructured Silica Nanoparticles as Biocompatible Carriers for Gene Delivery.
Potent Synergistic Effect on C-Myc-Driven Colorectal Cancers Using a Novel Indole-Substituted Quinoline with a Plk1 Inhibitor.
Probing the nanoparticle-AGO2 interaction for enhanced gene knockdown.
PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer.
Quantitative phospho-proteomics to investigate the Polo-like kinase 1-dependent phospho-proteome.
Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors.
Reciprocal Activation Between PLK1 and Stat3 Contributes to Survival and Proliferation of Esophageal Cancer Cells.
Reduced NR4A gene dosage leads to mixed myelodysplastic/myeloproliferative neoplasms in mice.
Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.
Regulatory functional territory of PLK-1 and their substrates beyond mitosis.
Replication stress, defective S-phase checkpoint and increased death in Plk2-deficient human cancer cells.
Resveratrol inhibits cell cycle progression by targeting Aurora kinase A and Polo-like kinase 1 in breast cancer cells.
Revisiting the molecular interactions between the tumor protein TCTP and the drugs sertraline/thioridazine.
RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells.
RNAi prodrugs decrease elevated mRNA levels of Polo-like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients.
RNAi prodrugs targeting Plk1 induce specific gene silencing in primary cells from pediatric T-acute lymphoblastic leukemia patients.
Role of NEK2A in Human Cancer and Its Therapeutic Potentials.
Role of polo-like kinase 4 (PLK4) in epithelial cancers and recent progress in its small molecule targeting for cancer management.
Roles of Polo-like kinase 3 in suppressing tumor angiogenesis.
ROS-Responsive Polymeric Micelles for Triggered Simultaneous Delivery of PLK1 Inhibitor/miR-34a and Effective Synergistic Therapy in Pancreatic Cancer.
ROS-Responsive Polymeric siRNA Nanomedicine Stabilized by Triple Interactions for the Robust Glioblastoma Combinational RNAi Therapy.
SAPK pathways and p53 cooperatively regulate PLK4 activity and centrosome integrity under stress.
ScFv-Decorated PEG-PLA-Based Nanoparticles for Enhanced siRNA Delivery to Her2(+) Breast Cancer.
Selective Cell Penetrating Peptide-Functionalized Envelope-Type Chimeric Lipopepsomes Boost Systemic RNAi Therapy for Lung Tumors.
Selectivity-determining residues in Plk1.
Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical development.
Sensitivity of TP53-Mutated Cancer Cells to the Phytoestrogen Genistein Is Associated With Direct Inhibition of Plk1 Activity.
Sialic Acid-Targeted Nanovectors with Phenylboronic Acid-Grafted Polyethylenimine Robustly Enhance siRNA-Based Cancer Therapy.
Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.
Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells.
Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression.
Simultaneous PLK1 inhibition improves local tumour control after fractionated irradiation.
Single-step assembly of cationic lipid-polymer hybrid nanoparticles for systemic delivery of siRNA.
Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals.
Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.
SPDEF inhibits prostate carcinogenesis by disrupting a positive feedback loop in regulation of the Foxm1 oncogene.
Structural basis for the inhibition of Polo-like kinase 1.
Structural insights into the inhibitor binding and new inhibitor design to Polo-Like Kinase-1 Polo-Box Domain using computational studies.
Structure of wild-type Plk-1 kinase domain in complex with a selective DARPin.
Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold.
Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK.
Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS-mutant cancer.
Systematic expression analysis of WEE family kinases reveals the importance of PKMYT1 in breast carcinogenesis.
Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome.
Targeted Delivery of CRISPR/Cas9-Mediated Cancer Gene Therapy via Liposome-Templated Hydrogel Nanoparticles.
Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis.
Targeting cell cycle by ?-carboline alkaloids in vitro: Novel therapeutic prospects for the treatment of cancer.
Targeting kinases with thymoquinone: a molecular approach to cancer therapeutics.
Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.
Targeting Polo-like Kinase 1 by a Novel Pyrrole-imidazole Polyamide-Hoechst Conjugate Suppresses Tumor Growth in vivo.
Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.
Targeting polo-like kinase 1 for cancer therapy.
Targeting polo-like kinase 1 suppresses essential functions of alloreactive T cells.
Targeting Polo-like kinase in cancer therapy.
The CINs of Polo-Like Kinase 1 in Cancer.
The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis.
The Discovery of Polo-Like Kinase 4 Inhibitors: Identification of (1R,2S)-2-(3-((E)-4-(((cis)-2,6-Dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a Potent, Orally Active Antitumor Agent.
The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.
The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas.
The dual role of BI 2536, a small-molecule inhibitor that targets PLK1, in induction of apoptosis and attenuation of autophagy in neuroblastoma cells.
The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor Metastasis.
The expression of PLK-1 in cervical carcinoma: a possible target for enhancing chemosensitivity.
The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?
The Multifaced Role of STAT3 in Cancer and Its Implication for Anticancer Therapy.
The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation.
The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin's lymphoma: A Phase I, open-label, single dose-escalation study.
The Plk1 inhibitor BI 2536 temporarily arrests primary cardiac fibroblasts in mitosis and generates aneuploidy in vitro.
The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma.
The potential mechanism of action of Sorcin and its interacting proteins.
The responses of cancer cells to PLK1 inhibitors reveal a novel protective role for p53 in maintaining centrosome separation.
The RNA helicase/transcriptional co-regulator, p68 (DDX5), stimulates expression of oncogenic protein kinase, Polo-like kinase-1 (PLK1), and is associated with elevated PLK1 levels in human breast cancers.
The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.
Therapeutic relevance of the protein phosphatase 2A in cancer.
Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
Therapeutic targeting of the PLK1-PRC1-axis triggers cell death in genomically silent childhood cancer.
Therapeutic Targeting PLK1 by ON-01910.Na Is Effective in Local Treatment of Retinoblastoma.
Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies.
Transient genomic instability drives tumorigenesis through accelerated clonal evolution.
Tumor inhibition by genomically integrated inducible RNAi-cassettes.
Tumor regression by combination antisense therapy against Plk1 and Bcl-2.
Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer.
Tuned Density of Anti-Tissue Factor Antibody Fragment onto siRNA-Loaded Polyion Complex Micelles for Optimizing Targetability into Pancreatic Cancer Cells.
Vitamin E-Conjugated Phosphopeptide Inhibitor of the Polo-Box Domain of Polo-Like Kinase 1.
Volasertib suppresses the growth of human hepatocellular carcinoma
Wnt5a-induced docking of Plk1 on HEF1 promotes HEF1 translocation and tumorigenesis.
[Enhancive Effect of PLK1 Gene Silencing onSensitivity of K562/A02 Cells to Adriamycin.]
[Mining Polo-Box domain of Polo-like kinase 1 as a new therapeutic target for cancer].
Neoplasms, Radiation-Induced
Polo-like kinase 1 (Plk1) overexpression enhances ionizing radiation-induced cancer formation in mice.
Nervous System Diseases
Structure-based design and confirmation of peptide ligands for neuronal polo-like kinase to promote neuroregeneration.
Neurilemmoma
Polo-like kinase 1 as a therapeutic target for malignant peripheral nerve sheath tumors (MPNST) and schwannomas.
Neuroblastoma
High levels of polo-like kinase 1 and phosphorylated translationally controlled tumor protein indicate poor prognosis in neuroblastomas.
Participation of type II protein kinase A in the retinoic acid-induced growth inhibition of SH-SY5Y human neuroblastoma cells.
Phosphorylation of endogenous proteins by adenosine 3':5'-monophosphate-dependent protein kinase in mouse neuroblastoma cells.
Polo-like kinase 1 inhibition sensitizes neuroblastoma cells for vinca alkaloid-induced apoptosis.
Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma.
Polo-Like Kinase 4 (PLK4) Is Overexpressed in Central Nervous System Neuroblastoma (CNS-NB).
Polo-like kinase 4 mediates epithelial-mesenchymal transition in neuroblastoma via PI3K/Akt signaling pathway.
Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells.
The dual role of BI 2536, a small-molecule inhibitor that targets PLK1, in induction of apoptosis and attenuation of autophagy in neuroblastoma cells.
The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.
Neurofibrosarcoma
Polo-like kinase 1 as a therapeutic target for malignant peripheral nerve sheath tumors (MPNST) and schwannomas.
Neutropenia
Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitor.
PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis.
Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical development.
Nevus
Multiple agminated Spitz nevi arising on a café au lait macule: review of the literature with contribution of another case.
Oral Submucous Fibrosis
Immunohistochemical expression of polo-like kinase 1 in oral squamous cell carcinoma and oral submucous fibrosis.
Osteoarthritis
siRNA targeting PLK-1 induces apoptosis of synoviocytes in rheumatoid arthritis.
Osteosarcoma
BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity.
CHOP negatively regulates Polo-like kinase 2 expression via recruiting C/EBP? to the upstream-promoter in human osteosarcoma cell line during ER stress.
Cytotoxic effects of 15d-PGJ2 against osteosarcoma through ROS-mediated AKT and cell cycle inhibition.
Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma.
Polo-Like Kinase 1 as a Potential Therapeutic Target for Osteosarcoma.
Poly-l-lysine Functionalized Large Pore Cubic Mesostructured Silica Nanoparticles as Biocompatible Carriers for Gene Delivery.
T-cell activation and early gene response in dogs.
Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.
Targeting the centrosome and polo-like kinase 4 in osteosarcoma.
Upregulation of Polo-like kinase 2 gene expression by GATA-1 acetylation in human osteosarcoma MG-63 cells.
Ovarian Neoplasms
Aurora Borealis (Bora), Which Promotes Plk1 Activation by Aurora A, Has an Oncogenic Role in Ovarian Cancer.
Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability.
Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage.
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI).
pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1.
Polo-like kinase PLK 2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer.
Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamics.
Therapeutic Gene Silencing Using Targeted Lipid Nanoparticles in Metastatic Ovarian Cancer.
YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects.
Pancreatic Neoplasms
A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer.
A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors.
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts.
Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer.
Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancer.
Phase 1 study of rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer.
Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.
RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells.
ROS-Responsive Polymeric Micelles for Triggered Simultaneous Delivery of PLK1 Inhibitor/miR-34a and Effective Synergistic Therapy in Pancreatic Cancer.
Vaccinia-related kinase 2 drives pancreatic cancer progression by protecting Plk1 from Chfr-mediated degradation.
Validation of Polo-like kinase 1 as a therapeutic target in pancreatic cancer cells.
Parkinson Disease
Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors.
Identification of the PLK2-dependent phosphopeptidomeby quantitative proteomics.
Insulin Resistance Promotes Parkinson's Disease through Aberrant Expression of ?-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling.
Selective and brain-permeable polo-like kinase-2 (Plk-2) inhibitors that reduce ?-synuclein phosphorylation in rat brain.
Pituitary Neoplasms
Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells.
Plasmacytoma
Resolution and general properties of different types of ribosomal protein kinases in mouse plasmocytoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells.
Integrated analysis of CRLF2 signaling in acute lymphoblastic leukemia identifies Polo-like kinase 1 as a potential therapeutic target.
Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
Prion Diseases
Overexpression of PLK3 Mediates the Degradation of Abnormal Prion Proteins Dependent on Chaperone-Mediated Autophagy.
Prostatic Intraepithelial Neoplasia
Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of Polo-like kinase-1.
Prostatic Neoplasms
A ribonucleoprotein octamer for targeted siRNA delivery.
Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.
Apoptotic effects of genistein, biochanin-A and apigenin on LNCaP and PC-3 cells by p21 through transcriptional inhibition of polo-like kinase-1.
Cotargeting Polo-Like Kinase 1 and the Wnt/?-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer.
Cross Talk between Wnt/?-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications.
Inhibition of Polo-like Kinase 1 (Plk1) Enhances the Antineoplastic Activity of Metformin in Prostate Cancer.
Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of Polo-like kinase-1.
Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer.
Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer.
Polo-like kinase (Plk) 1 as a target for prostate cancer management.
Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer.
Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation.
Polo-like kinase 1 induces epithelial-to-mesenchymal transition and promotes epithelial cell motility by activating CRAF/ERK signaling.
Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades.
Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development.
Polo-like kinase 3 is associated with poor prognosis and regulates proliferation and metastasis in prostate cancer.
Prostate cancer: PLK-1 inhibition improves abiraterone efficacy.
Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.
Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors.
Rectal Neoplasms
Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer.
Upregulated Polo-Like Kinase 1 Expression Correlates with Inferior Survival Outcomes in Rectal Cancer.
Retinoblastoma
Anexelekto /MER Tyrosine Kinase inhibitor ONO-7475 growth arrests and kills FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Mutant Acute Myeloid Leukemia cells by diverse mechanisms.
Inhibition of polo-like kinase 1 promotes hyperthermia sensitivity via inactivation of heat shock transcription factor 1 in human retinoblastoma cells.
Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
Rhabdoid Tumor
A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.
Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma.
Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor.
Rhabdomyosarcoma
A Perspective on Polo-Like Kinase-1 Inhibition for the Treatment of Rhabdomyosarcomas.
Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas.
Sarcoma
Inhibition of polo like kinase 1 in sarcomas induces apoptosis that is dependent on Mcl-1 suppression.
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI).
Viral src gene products are related to the catalytic chain of mammalian cAMP-dependent protein kinase.
Sarcoma, Avian
Cytosolic malic dehydrogenase activity is associated with a putative substrate for the transforming gene product of Rous sarcoma virus.
Protein kinase and its regulatory effect on reverse transcriptase activity of Rous sarcoma virus.
Sarcoma, Ewing
Synergistic induction of apoptosis by a polo-like kinase 1 inhibitor and microtubule-interfering drugs in Ewing sarcoma cells.
Schistosomiasis
Algorithmic Mapping and Characterization of the Drug-Induced Phenotypic-Response Space of Parasites Causing Schistosomiasis.
Schistosoma mansoni Polo-like kinase 1: A mitotic kinase with key functions in parasite reproduction.
Schistosoma mansoni Polo-like kinases and their function in control of mitosis and parasite reproduction.
Seizures
Mammalian target of rapamycin complex 1 activation negatively regulates Polo-like kinase 2-mediated homeostatic compensation following neonatal seizures.
Sepsis
LncRNA DANCR improves the dysfunction of the intestinal barrier and alleviates epithelial injury by targeting the miR-1306-5p/PLK1 axis in sepsis.
Polo-like kinase 1 protects intestinal epithelial cells from apoptosis during sepsis via the nuclear factor-?B pathway.
Skin Neoplasms
Polo-like kinase 1 (Plk1) in non-melanoma skin cancers.
Small Cell Lung Carcinoma
An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).
Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.
Squamous Cell Carcinoma of Head and Neck
Immunohistochemical expression of polo-like kinase 1 in oral squamous cell carcinoma and oral submucous fibrosis.
Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.
Stomach Neoplasms
Advances of Molecular Targeted Therapy in Gastric Cancer.
BI2536, a potent and selective inhibitor of polo-like kinase 1, in combination with cisplatin exerts synergistic effects on gastric cancer cells.
Clinical Significance of Polo-Like Kinase 4 as a Marker for Advanced Tumor Stage and Dismal Prognosis in Patients With Surgical Gastric Cancer.
Effect of PLK1 inhibition on cisplatin-resistant gastric cancer cells.
Effects of PLK1 on proliferation, invasion and metastasis of gastric cancer cells through epithelial-mesenchymal transition.
Expression patterns of polo-like kinase 1 in human gastric cancer.
Gastric Cancer Patients with High PLK1 Expression and DNA Aneuploidy Correlate with Poor Prognosis.
Helicobacter pylori promotes gastric epithelial cell survival through the PLK1/PI3K/Akt pathway.
Inhibitory effect of Polo-like kinase 1 depletion on mitosis and apoptosis of gastric cancer cells.
Involvement of Polo-like kinase 1 (Plk1) in quiescence regulation of cancer stem-like cells of the gastric cancer cell lines.
MicroRNA-505 suppresses gastric cancer cell proliferation and invasion by directly targeting Polo-like kinase-1.
Pharmacogenomic Analysis Reveals CCNA2 as a Predictive Biomarker of Sensitivity to Polo-Like Kinase I Inhibitor in Gastric Cancer.
Silencing of polo-like kinase 2 increases cell proliferation and decreases apoptosis in SGC-7901 gastric cancer cells.
[Mitosis arrest caused by inhibition of PLK1 expression in gastric cancer MKN45 cells]
Synucleinopathies
Identification of the PLK2-dependent phosphopeptidomeby quantitative proteomics.
Thyroid Carcinoma, Anaplastic
Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma.
PLK1 gene suppresses cell invasion of undifferentiated thyroid carcinoma through the inhibition of CD44v6, MMP-2 and MMP-9.
Thyroid Neoplasms
[Cellular tumor markers in thyroid cancer]
Triple Negative Breast Neoplasms
Anticancer effects of radiation therapy combined with Polo-Like Kinase 4 (PLK4) inhibitor CFI-400945 in triple negative breast cancer.
Combination Treatment of Polo-Like Kinase 1 and Tankyrase-1 Inhibitors Enhances Anticancer Effect in Triple-negative Breast Cancer Cells.
Deciphering the performance of polo-like kinase 1 in triple-negative breast cancer progression according to the centromere protein U-phosphorylation pathway.
Dendrimer mediated targeting of siRNA against polo-like kinase for the treatment of triple negative breast cancer.
Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer.
Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.
Selective transferrin coating as a facile strategy to fabricate BBB-permeable and targeted vesicles for potent RNAi therapy of brain metastatic breast cancer in vivo.
Systemic Administration of siRNA with Anti-HB-EGF Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer.
Tuberous Sclerosis
Hamartin, the tuberous sclerosis complex 1 gene product, interacts with polo-like kinase 1 in a phosphorylation-dependent manner.
Urinary Bladder Neoplasms
Down-regulation of Polo-like kinase 4 (PLK4) induces G1 arrest via activation of the p38/p53/p21 signaling pathway in bladder cancer.
Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer.
Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer.
PLK-1 Silencing in Bladder Cancer by siRNA Delivered With Exosomes.
Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells.
Targeted inhibition of Polo-like kinase 1 by a novel small-molecule inhibitor induces mitotic catastrophe and apoptosis in human bladder cancer cells.
Uterine Cervical Neoplasms
[Knockdown of Polo-like kinase 1 (PLK1) inhibits the growth of cervical cancer HeLa cells].
Virus Diseases
Dysregulation of the polo-like kinase pathway in CD4+ T cells is characteristic of pathogenic simian immunodeficiency virus infection.